These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas. Matter MS; Chijioke O; Savic S; Bubendorf L Transl Lung Cancer Res; 2020 Dec; 9(6):2645-2655. PubMed ID: 33489824 [TBL] [Abstract][Full Text] [Related]
83. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements? Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208 [TBL] [Abstract][Full Text] [Related]
84. Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase ( Tang Z; Wang L; Tang G; Medeiros LJ Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412611 [TBL] [Abstract][Full Text] [Related]
85. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. Davies KD; Le AT; Sheren J; Nijmeh H; Gowan K; Jones KL; Varella-Garcia M; Aisner DL; Doebele RC J Thorac Oncol; 2018 Oct; 13(10):1474-1482. PubMed ID: 29935306 [TBL] [Abstract][Full Text] [Related]
86. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130 [TBL] [Abstract][Full Text] [Related]
87. Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay. Rodríguez-Antolín C; Rosas-Alonso R; Cruz P; Higuera O; Sánchez-Cabrero D; Esteban-Rodríguez I; Peláez-García A; Fernández Montaño VE; Rodríguez-Jiménez C; Ibáñez de Cáceres I; de Castro J Oncologist; 2021 Jun; 26(6):e908-e912. PubMed ID: 33682977 [TBL] [Abstract][Full Text] [Related]
88. Assessment of Huang Q; Deng Q; Jiang L; Fang R; Qiu Y; Wang P; Zhou JX; Yang H Oncol Lett; 2016 Mar; 11(3):1651-1656. PubMed ID: 26998057 [TBL] [Abstract][Full Text] [Related]
89. RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients. Aguado C; Giménez-Capitán A; Román R; Rodríguez S; Jordana-Ariza N; Aguilar A; Cabrera-Gálvez C; Rivas-Corredor C; Lianes P; Viteri S; Moya I; Molina-Vila MA Diagnostics (Basel); 2020 Dec; 11(1):. PubMed ID: 33374879 [TBL] [Abstract][Full Text] [Related]
90. Emerging oncogenic fusions other than Suda K; Mitsudomi T Transl Lung Cancer Res; 2020 Dec; 9(6):2618-2628. PubMed ID: 33489822 [TBL] [Abstract][Full Text] [Related]
91. Clinical Utility Validation of an Automated Ultrarapid Gene Fusion Assay for NSCLC. Buglioni A; Caffes PL; Hessler MG; Mansfield AS; Lo YC JTO Clin Res Rep; 2022 Dec; 3(12):100434. PubMed ID: 36536899 [TBL] [Abstract][Full Text] [Related]
92. Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC. Hofman V; Heeke S; Bontoux C; Chalabreysse L; Barritault M; Bringuier PP; Fenouil T; Benzerdjeb N; Begueret H; Merlio JP; Caumont C; Piton N; Sabourin JC; Evrard S; Syrykh C; Vigier A; Brousset P; Mazieres J; Long-Mira E; Benzaquen J; Boutros J; Allegra M; Tanga V; Lespinet-Fabre V; Salah M; Bonnetaud C; Bordone O; Lassalle S; Marquette CH; Ilié M; Hofman P JTO Clin Res Rep; 2023 Feb; 4(2):100457. PubMed ID: 36718140 [TBL] [Abstract][Full Text] [Related]
93. Detection of Li N; Chen Z; Huang M; Zhang D; Hu M; Jiao F; Quan M Front Cell Dev Biol; 2022; 10():1035033. PubMed ID: 36589752 [No Abstract] [Full Text] [Related]
94. The potential and limitation of targeted chromosomal breakpoint sequencing for the Hung MS; Lin YC; Chen FF; Jiang YY; Fang YH; Lu MS; Lin CK; Yang TM; Lung J; Chen CC; Lee KD; Tsai YH Am J Cancer Res; 2022; 12(5):2376-2386. PubMed ID: 35693072 [No Abstract] [Full Text] [Related]
95. Genomic landscape of 891 RET fusions detected across diverse solid tumor types. Parimi V; Tolba K; Danziger N; Kuang Z; Sun D; Lin DI; Hiemenz MC; Schrock AB; Ross JS; Oxnard GR; Huang RSP NPJ Precis Oncol; 2023 Jan; 7(1):10. PubMed ID: 36690680 [TBL] [Abstract][Full Text] [Related]
96. Robust Performance of the Novel Research-Use-Only Idylla GeneFusion Assay Using a Diverse Set of Pathological Samples with a Proposed 1-Day Workflow for Advanced NSCLC Evaluation. Leone A; Muscarella LA; Graziano P; Tornese A; Grillo LR; Di Lorenzo A; Bronzini M; Scarpino S; Sparaneo A; Rossi G Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612287 [TBL] [Abstract][Full Text] [Related]
97. Development of a high-throughput and sensitive assay of fusion genes in lung cancer by array-based MALDI-TOFMS. Wu HT; Li K; Wang G; Yang XX; Zhu A; Xu XP; Li M; Wu YS; Liu TC RSC Adv; 2018 Aug; 8(49):27935-27945. PubMed ID: 35548167 [TBL] [Abstract][Full Text] [Related]
98. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization. Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438 [TBL] [Abstract][Full Text] [Related]